Proton Therapy in Head and Neck Cancer Treatment: State of the Problem and Development Prospects (Review)

por Gordon, K.B., Smyk, D.I., Gulidov, I.A.
Publicado 2021

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

por Lebwohl, M.G., Gordon, K.B., Gallo, G., Zhang, L., Paul, C.
Publicado 2019

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory

por Gordon, KB, Kimball, AB, Chau, D, Viswanathan, HN, Li, J, Revicki, DA, Kricorian, G, Ortmeier, BG
Publicado 2014

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

por Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.
Publicado 2021

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

por Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Publicado 2017

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, doubl...

por Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.
Publicado 2020